Chordate Medical announces that the Company's shares are traded on the Nasdaq First North Growth Market ("First North") as of today, February 15th, 2022. Chordate has received final approval from Nasdaq Stockholm AB and the Company's shares are traded on First North as of today with unchanged short name CMH and ISIN code SE0009495559. The shareholders of Chordate do not need to take any action in connection with this.
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the list change and Certified Adviser. Wistrand Advokatbyrå AB is Chordate's legal advisor.
For more information, please contact:
Anders Weilandt, CEO
Cell: +46 733-874277
The following documents can be retrieved from beQuoted
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at www.chordate.com
Chordate's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vastra Hamnen Corporate Finance AB, +46 40 200 250, email@example.com.